Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Oct 20, 2020 4:33pm
124 Views
Post# 31749726

RE:RE:RE:Hilarious

RE:RE:RE:Hilarious
reverse, redefine, spotless, and blemish are all product regimes that could theoretically have .2% lightener in them. using them in combination might actually produce a .4% or higher effect, and since it is delivered as an integrated regime/am/pm treatment, that is one way to deal with pharma grade fda approval barriers. . I am not a scientist and I don't know if that is how it would work. But this is something they should look at within the partnership. Rodan has enough smart people to figure it out. I thought this was part of the proprietary technology plus ingredients theory, but per yesterday's tweet it seems like that is not the case and something independent (or integrated), perhaps with its own spotlight is under preparation... until then, when is Howie and his band of lawyers going to giddy up and Tinyi or SGLT2 2.0?
Bullboard Posts